-
Press Release
Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
-
Press Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Press Release
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Press Release
Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
-
Press Release
Novartis receives complete response letter from U.S. FDA for inclisiran
-
Press Release
Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention
-
Press Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Press Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Press Release
Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps
-
Press Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
-
Press Release
Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis
-
Press Release
Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma